Izotropic Corp. (TSE:IZO)
:IZO
Top Page
Izotropic
(IZO)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.23
▼(-18.21% Downside)
Action:ReiteratedDate:03/29/26
The score is primarily constrained by weak financial performance (no revenue, persistent losses, negative equity, and ongoing cash burn). Technicals are mixed with modest short-term strength but weaker longer-term trend signals. Valuation is difficult to support given negative earnings and no dividend yield data.
Positive Factors
Dedicated breast CT platform
Izotropic’s focused product strategy—developing the IzoView dedicated breast CT—represents a durable business model advantage in a specialized medical device niche. A dedicated modality can create clinical differentiation, higher switching costs, and clearer value propositions for screening and diagnostics over time.
Negative Factors
No revenue / continued losses
Absence of revenue and persistent net losses are structural weaknesses: without validated commercial sales the business model remains unproven, external financing is necessary, and operating leverage cannot be achieved. This constrains long-term margin sustainability and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Dedicated breast CT platform
Izotropic’s focused product strategy—developing the IzoView dedicated breast CT—represents a durable business model advantage in a specialized medical device niche. A dedicated modality can create clinical differentiation, higher switching costs, and clearer value propositions for screening and diagnostics over time.
Read all positive factors
Izotropic (IZO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$15.93M
Dividend YieldN/A
Average Volume (3M)43.33K
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue GrowthN/A
EPS Growth11.68%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding67,784,676
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Izotropic Business Overview & Revenue Model
Company Description
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. Th...
How the Company Makes Money
null...
Izotropic Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -32.56K | -48.90K | -59.07K | -30.88K | -6.87K | -1.63K |
| EBITDA | -2.37M | -2.14M | -1.60M | -5.33M | -6.63M | -4.97M |
| Net Income | -2.52M | -3.14M | -1.56M | -5.66M | -6.67M | -4.98M |
Balance Sheet | ||||||
| Total Assets | 685.34K | 414.73K | 232.38K | 442.11K | 2.27M | 4.69M |
| Cash, Cash Equivalents and Short-Term Investments | 364.08K | 274.11K | 38.60K | 165.69K | 1.86M | 4.06M |
| Total Debt | 3.14M | 2.76M | 2.06M | 2.14M | 2.03M | 0.00 |
| Total Liabilities | 6.03M | 5.27M | 4.08M | 3.52M | 2.64M | 169.28K |
| Stockholders Equity | -5.34M | -4.86M | -3.85M | -3.07M | -374.59K | 4.52M |
Cash Flow | ||||||
| Free Cash Flow | -961.18K | -637.37K | -593.57K | -3.30M | -4.79M | -3.08M |
| Operating Cash Flow | -961.18K | -636.23K | -593.57K | -3.27M | -4.76M | -3.08M |
| Investing Cash Flow | 0.00 | -1.14K | 0.00 | -36.18K | -24.23K | 0.00 |
| Financing Cash Flow | 1.11M | 872.78K | 468.18K | 1.61M | 2.58M | 6.53M |
Izotropic Technical Analysis
Neutral
0.28
Price Trends
0.23
Positive
0.28
Negative
0.30
Negative
Market Momentum
>-0.01
Negative
55.08
Neutral
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.08 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:IZO.
Izotropic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$20.64M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
49 Neutral | C$418.36M | -8.67 | ― | ― | 34.85% | -62.50% | |
48 Neutral | C$64.11M | -32.47 | ― | ― | -21.89% | 26.36% | |
45 Neutral | C$15.93M | -9.29 | 53.94% | ― | ― | 11.68% | |
42 Neutral | C$56.12M | -1.50 | -220.14% | ― | 209.29% | 35.38% | |
41 Neutral | C$37.17M | -21.43 | -434.25% | ― | ― | 10.97% |
* Healthcare Sector Average
TSE:IZO
Izotropic
0.24
-0.07
-21.67%
TSE:EDT
Spectral Medical
1.43
0.66
85.71%
TSE:BUX
BioMark Diagnostics
0.61
0.34
125.93%
TSE:PINK
Perimeter Medical Imaging AI
0.45
0.02
3.49%
TSE:SONA
Sona Nanotech Inc
0.33
0.04
12.07%
TSE:VPT
VentriPoint Diagnostics
0.11
-0.06
-35.29%
Izotropic Corporate Events
Business Operations and StrategyProduct-Related Announcements
Izotropic Africa Pursues Moroccan Partnership to Advance Breast CT Expansion
Positive
Feb 25, 2026
Izotropic’s newly formed Casablanca-based venture, Izotropic Africa, is being structured to license, market, and distribute the IzoView Breast CT Imaging System and follow-on products across Africa and the Gulf Cooperation Council, with Izot...
Business Operations and Strategy
Izotropic Moves to Establish African and GCC Hub for Breast CT Imaging
Positive
Feb 18, 2026
Izotropic Corporation has signed a letter agreement with a business group to create Izotropic Africa, a Casablanca-based entity that will license, market, and distribute the IzoView Breast CT system and follow-on products across Africa and the Gul...
Private Placements and Financing
Izotropic Raises Working Capital and Settles Debt with Equity Units
Positive
Feb 4, 2026
Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million units priced at $0.25, each carrying a share and three-year warrant, with proceeds earmarked for general working capital and contingent on regulatory approvals...
Business Operations and StrategyPrivate Placements and Financing
Izotropic Plans $300,000 Private Placement to Advance IzoView Breast CT Commercialization
Positive
Jan 28, 2026
Izotropic Corporation has provided a corporate update outlining its strategic priority to secure capital, with an emphasis on non-dilutive financing, to fund the commercialization of its IzoView Breast CT system and accelerate additional regulator...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Izotropic Shareholders Approve All AGM Resolutions and Lower Quorum Threshold
Positive
Dec 31, 2025
Izotropic Corporation reported that all resolutions presented at its Annual General and Special Meeting on December 29, 2025, were approved by shareholders, including the election of five directors for the coming year and the reappointment of its ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.